

香港聯合交易所有限公司
(香港交易及結算所有限公司全資附屬公司)

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

通告 CIRCULAR

Subject: **Delisting of HUBEI BIOCAUSE PHARMACEUTICAL (*ST) (SZSE Security Code: 000627) from SZSE**

Enquiry: **Participant General Enquiry Hotline¹ (Tel : 2840 3626 E-mail : trd@hkex.com.hk)**

Please note that HUBEI BIOCAUSE PHARMACEUTICAL (*ST) ("BIOCAUSE") has issued an [announcement](#) (Chinese only) on the Shenzhen Stock Exchange ("SZSE") website in which it is stated BIOCAUSE shares will be delisted from SZSE **effective from 30 September 2025**. Therefore, **effective the same day**, BIOCAUSE will be removed from the list of Special China Connect Securities.

The aforementioned change is also available on the "[Eligible Stocks](#)" section of the Connect Programmes webpage.

When providing services to clients on China Connect Securities, Exchange Participants are reminded to refer to the latest information including but not limited to the announcements issued by listed companies on the SZSE website.

Olivia Mak
Senior Vice President
Trading Department
Operations Division

¹ All calls to and from the Participant General Enquiry Hotline may be recorded. HKEX Privacy Policy Statement is available [here](#).